Riverpoint Medical, LLC appears in FDA records as the applicant for K263073, a Special 510(k) for Fast Absorbing PGLA. The September 29, 2026 decision was Substantially Equivalent, with the device classified under 21 CFR 878.4493 as an absorbable poly(glycolide/L-lactide) surgical suture, Class II, product code GAM, in the General and Plastic Surgery panel. The filing was received September 1, 2026 and was not reviewed by a third party. The submission states that the proposed suture products are substantially equivalent to a listed predicate, K120556 Fast Absorbing PGLA: Vilet Quick. [1][2][3]

The K263073 filing and its predicate

K263073 lists Riverpoint Medical, LLC at 825 NE 25th Ave., Portland, Oregon 97232, with Rose Nakaweesi as contact and a device trade name of Fast Absorbing PGLA. FDA’s decision letter identifies the regulation as 21 CFR 878.4493, Absorbable Poly(Glycolide/L-Lactide) Surgical Suture, Class II, product code GAM, and records the submission as dated and received September 1, 2026. The database entry shows a Special 510(k) with a Summary, no third-party review, no combination product status and no authorized Predetermined Change Control Plan. [1][2][3]

The submission’s conclusion states that the proposed suture products are substantially equivalent to the predicate device listed, K120556 Fast Absorbing PGLA: Vilet Quick. That predicate document, prepared in 2012, names Riverpoint Medical as submitter and lists trade names PGLA: Vilet and Fast Absorbing PGLA: Vilet Quick, with common names absorbable surgical sutures: PGLA. It also states that PGLA Quick suture is provided sterile as a single-use device. [2][5]

Documented product scope

Riverpoint Medical’s published site describes the company as designing, developing and manufacturing implantable textiles and fibers, organized around custom fibers, surgical coatings, implantable materials, finished devices and needles, with markets listed as sports medicine, orthopedics, wound closure, cardiovascular, oncology, ophthalmology and surgical headlights. The same site lists absorbable sutures in PGLA, PGA, PDO, PGCL and chromic gut, non-absorbable sutures in PTFE, polyester and UHMWPE, and suture anchors including pre-loaded titanium button, PEEK and all-suture designs. [4][9]

A separate page on the manufacturer’s site describes finished, sterile devices with custom private labeling and a wound closure portfolio of absorbable and non-absorbable suture materials and needle configurations. It also lists an oncology product line and synthetic absorbable punctal plugs made from polydioxanone (PDO) for post-surgical dry eye, alongside punctal needles. These are the manufacturer’s own descriptions of its offerings; the FDA record for K263073 covers Fast Absorbing PGLA specifically. [8]

Registration and establishment record

FDA establishment registration data lists RIVERPOINT MEDICAL LLC at 825 NE 25th Ave, Portland, OR 97232, registration number 3006981798, FEI number 3006981798, status Active, with a date of registration status in 2026 and Riverpoint Medical LLC as owner/operator. A search of the establishment registration and device listing database returns two results for Riverpoint Medical. The 2012 predicate summary gives the same Portland address and registration number 3006981798, with Douglas Rowley as contact. [5][6][7]

What the record does not establish

The linked collection for this profile contains one 510(k) record, K263073, with a Substantially Equivalent decision; that count reflects the filings retrieved as of November 20, 2026 and is not a measure of total company sales, total portfolio or safety performance. No recall records appear in the retrieved sample. The sources do not identify a parent company, brand ownership, customer list, certification set or commercial availability for Fast Absorbing PGLA, and the Portland address appears in FDA filings and the manufacturer’s contact page rather than as a verified corporate headquarters designation. [1][4][7]